Author Archives: William Looney and Ben Comer

Does Pharma Have a Debt Crisis Strategy?

The Obama Administration’s proposed fiscal budget for 2012 suggested that all bets are off for biopharmaceutical revenue safeguards, but it never had a chance with Congress, as evidenced by a unanimous no-thank-you from the Senate in late May. But that was before debt ceiling talks and the alleged possibility of a default emerged as the […]
Posted in Corporate Responsibility, Europe, Global, healthcare, leadership, pricing, Strategy | Tagged , , , , , | 1 Comment
  • Categories

  • Meta